Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?
Clin Breast Cancer. 2024 Jan 16:S1526-8209(24)00002-8. doi: 10.1016/j.clbc.2024.01.002. Online ahead of print.ABSTRACTThe introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer is regarded as one of the greatest achievements of the last decades in breast oncology. To date, palbociclib, abemaciclib and ribociclib are the 3 approved CDK4/6 inhibitors that combined with endocrine therapy are now considered as the standard first-line treatment of metastatic HR+/HER2- breast cancer. T...
Source: Clinical Breast Cancer - February 6, 2024 Category: Cancer & Oncology Authors: Ioanna Ploumaki Efthymios Triantafyllou Ioannis-Alexios Koumprentziotis Konstantinos Karampinos Konstantinos Drougkas Ioannis Karavolias Elias Kotteas Source Type: research
Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?
Clin Breast Cancer. 2024 Jan 16:S1526-8209(24)00002-8. doi: 10.1016/j.clbc.2024.01.002. Online ahead of print.ABSTRACTThe introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer is regarded as one of the greatest achievements of the last decades in breast oncology. To date, palbociclib, abemaciclib and ribociclib are the 3 approved CDK4/6 inhibitors that combined with endocrine therapy are now considered as the standard first-line treatment of metastatic HR+/HER2- breast cancer. T...
Source: Clinical Genitourinary Cancer - February 6, 2024 Category: Cancer & Oncology Authors: Ioanna Ploumaki Efthymios Triantafyllou Ioannis-Alexios Koumprentziotis Konstantinos Karampinos Konstantinos Drougkas Ioannis Karavolias Elias Kotteas Source Type: research
Cancers, Vol. 16, Pages 678: Macrophages Promote Subtype Conversion and Endocrine Resistance in Breast Cancer
Conclusion: Our study revealed the HER2-E subtype conversion during LNM in BC. Macrophages were the crucial cell type in TME, inducing the downregulation of HR and upregulation of HER2, probably via MNX1. Targeting macrophages or MNX1 may provide new avenues for endocrine therapy and targeted treatment of BC patients with LNM. (Source: Cancers)
Source: Cancers - February 5, 2024 Category: Cancer & Oncology Authors: Xiaoyan Zhang Fengyu Yang Zhijian Huang Xiaojun Liu Gan Xia Jieye Huang Yang Yang Junchen Li Jin Huang Yuxin Liu Ti Zhou Weiwei Qi Guoquan Gao Xia Yang Tags: Article Source Type: research
Symptoms and need for individualised support during the first year after primary treatment for breast cancer-A qualitative study
CONCLUSION: During the first year after primary treatment, patients with breast cancer describe how they try to manage by themselves, but express both unmet needs and a wish for extended and more individually tailored support. The healthcare professionals recognised that patients lack a structured plan for the first year and the need for continued support. This stresses a need for development of care models with special consideration towards individualised support after breast cancer treatment.NO PATIENT OR PUBLIC CONTRIBUTION: There was no patient or public involvement in the design or conduct of the study. The interview ...
Source: Clinical Breast Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Kristina Rooth Kay Sundberg Tina Gustavell Ann Langius-Ekl öf Linda Gellerstedt Source Type: research
Symptoms and need for individualised support during the first year after primary treatment for breast cancer-A qualitative study
CONCLUSION: During the first year after primary treatment, patients with breast cancer describe how they try to manage by themselves, but express both unmet needs and a wish for extended and more individually tailored support. The healthcare professionals recognised that patients lack a structured plan for the first year and the need for continued support. This stresses a need for development of care models with special consideration towards individualised support after breast cancer treatment.NO PATIENT OR PUBLIC CONTRIBUTION: There was no patient or public involvement in the design or conduct of the study. The interview ...
Source: Clinical Genitourinary Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Kristina Rooth Kay Sundberg Tina Gustavell Ann Langius-Ekl öf Linda Gellerstedt Source Type: research
Cancers, Vol. 16, Pages 619: Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
an
Ajay Dhakal
Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against...
Source: Cancers - January 31, 2024 Category: Cancer & Oncology Authors: Niraj Neupane Sawyer Bawek Sayuri Gurusinghe Elham Moases Ghaffary Omid Mirmosayyeb Sangharsha Thapa Carla Falkson Ruth O ’Regan Ajay Dhakal Tags: Review Source Type: research
Cancers, Vol. 16, Pages 552: Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
This article discusses the latest progress in treatments like oral selective ER degraders (SERDs), complete estrogen receptor antagonists (CERANs), selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimera (PROTAC) degraders, and combinations of CDK4/6 inhibitors with endocrine therapy. The focus is specifically on those compounds that have transitioned into phases of clinical development. (Source: Cancers)
Source: Cancers - January 27, 2024 Category: Cancer & Oncology Authors: Rohan Kalyan Rej Joyeeta Roy Srinivasa Rao Allu Tags: Review Source Type: research
Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
ConclusionTo generate nomograms that predicted DFS and OS, independent predictors of DFS in ER-positive/HER2-negative breast cancer patients were chosen. The nomograms successfully stratified patients into prognostic categories and worked well in both internal validation and external validation. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - January 25, 2024 Category: Cancer & Oncology Source Type: research
Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery
AbstractDermatomyositis (DM) is an autoimmune disease that causes proximal muscle weakness in the extremities leading to severe immobility and dysphagia. Approximately 20% of patients with DM are positive for anti-TIF-1 γ antibody and frequently accompanied by malignant tumors. Although DM remission after tumor resection has been reported, the indications for surgery in patients with severe DM are unknown. Herein, we report a case of a 79-year-old Japanese woman who presented with breast cancer and anti-TIF-1γ an tibody-positive DM. She became bedridden shortly after DM onset. Although pulsed steroid therapy, intravenous...
Source: International Cancer Conference Journal - January 25, 2024 Category: Cancer & Oncology Source Type: research
Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
Breast cancer, a complex and varied disease, has four distinct subtypes based on estrogen receptor and human epidermal growth factor receptor 2 (HER2) levels, among which a significant subtype known as HR+/HER2-breast cancer that has spurred numerous research. The prevalence of breast cancer and breast cancer-related death are the most serious threats to women’s health worldwide. Current progress in treatment strategies for HR+/HER2-breast cancer encompasses targeted therapy, endocrine therapy, genomic immunotherapy, and supplementing traditional methods like surgical resection and radiotherapy. This review article summa...
Source: Frontiers in Pharmacology - January 24, 2024 Category: Drugs & Pharmacology Source Type: research
Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis
ConclusionsEvidence in the setting of predictive tests for extended endocrine therapy is sparse. Most relevant studies investigated the use of BCI, but these study populations were largely restricted to a single age, race, and ethnicity group. Future studies should evaluate a variety of biomarkers in diverse populations. Without sufficient evidence, physicians and patients face a difficult decision in balancing the benefits and risks of endocrine therapy extension. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research
Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
ConclusionMonochemotherapy (Docetaxel) plus dual-target (Trastuzumab and Pertuzumab) therapy remains the optimal choice among all first-line treatment options for ABC. The combination of trastuzumab with TKIs (Pyrotinib) demonstrated a significant improvement in PFS and ORR, but further data are warranted to confirm the survival benefit. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - January 20, 2024 Category: Cancer & Oncology Source Type: research
Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study
ConclusionDPS showed high accuracy and predictive performance, was able to stratify patients into low or high-risk, and considering its cost and rapidity, has the potential to offer clinical utility. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 20, 2024 Category: Cancer & Oncology Source Type: research
Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews
ConclusionsThe evidence-base on ET adherence determinants is extensive. Future empirical studies should focus on less well-researched areas and settings. The determinants themselves are numerous and complex in indicating that adherence support should be multifaceted, addressing multiple determinants. (Source: Cancer Medicine)
Source: Cancer Medicine - January 19, 2024 Category: Cancer & Oncology Authors: Adam Todd,
Catherine Waldron,
Lucy McGeagh,
Ruth Norris,
Iakov Bolnykh,
Sarah Jane Stewart,
Joanna Slodkowska ‐Barabasz,
Zoe Moon,
Caitriona Cahir,
Sue Thompson,
Victoria Harmer,
Mary Wells,
Eila Watson,
Linda Sharp,
the SWEET Research Tea Tags: RESEARCH ARTICLE Source Type: research
Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication
CONCLUSION: We mapped frequency and types of ribociclib-induced CAEs. An interdisciplinary management of CAEs incorporated into routine care may reduce the rate of drug discontinuation thus potentially contributing to better long-term outcomes.PMID:38242689 | DOI:10.1093/oncolo/oyae004 (Source: The Oncologist)
Source: The Oncologist - January 19, 2024 Category: Cancer & Oncology Authors: Riccardo Giovanni Borroni Michela Bartolini Mariangela Gaudio Flavia Jacobs Chiara Benvenuti Riccardo Gerosa Paola Tiberio Sofia Ada Assunta Maria Manara Alessandra Solferino Armando Santoro Rita De Sanctis Source Type: research
